These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 30829792)

  • 21. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.
    Haahr H; Fita EG; Heise T
    Clin Pharmacokinet; 2017 Apr; 56(4):339-354. PubMed ID: 27696221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review.
    Jendle J; Martin SA; Milicevic Z
    Expert Opin Investig Drugs; 2012 Oct; 21(10):1463-74. PubMed ID: 22799463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy.
    Hirsch IB; Buse JB; Leahy J; McGill JB; Peters A; Rodbard HW; Rubin RR; Skyler JS; Verderese CA; Riddle MC
    Diabetes Obes Metab; 2014 Mar; 16(3):206-14. PubMed ID: 23711193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hypoglycemia].
    Gupta PS; Green AN; Chowdhury TA
    Praxis (Bern 1994); 2011 Oct; 100(21):1303-5. PubMed ID: 22012756
    [No Abstract]   [Full Text] [Related]  

  • 28. Do GLP-1-based therapies increase cancer risk?
    Nauck MA; Friedrich N
    Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S245-52. PubMed ID: 23882053
    [No Abstract]   [Full Text] [Related]  

  • 29. Potential Issues With New Basal Insulin/GLP-1 Fixed Combinations.
    Shastay A
    Home Healthc Now; 2019; 37(2):120-121. PubMed ID: 30829792
    [No Abstract]   [Full Text] [Related]  

  • 30. First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.
    Rendell M
    Drugs Today (Barc); 2015 Mar; 51(3):185-96. PubMed ID: 25876562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin degludec + liraglutide: a complementary combination.
    Stinkens K; Peene B; Mathieu C
    Expert Opin Biol Ther; 2016 Sep; 16(9):1171-7. PubMed ID: 27484310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical use of the co-formulation of insulin degludec and insulin aspart.
    Kumar A; Awata T; Bain SC; Ceriello A; Fulcher GR; Unnikrishnan AG; Arechavaleta R; Gonzalez-Gálvez G; Hirose T; Home PD; Kaku K; Litwak L; Madsbad S; Pinget M; Mehta R; Mithal A; Tambascia M; Tibaldi J; Christiansen JS
    Int J Clin Pract; 2016 Aug; 70(8):657-67. PubMed ID: 27384031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
    Vedtofte L; Knop FK; Vilsbøll T
    Expert Rev Clin Pharmacol; 2015 May; 8(3):273-82. PubMed ID: 25816888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]     [New Search]
    of 2.